Theresa Nguyen Wenker1, Mimi C Tan1,2, Yan Liu1, Hashem B El-Serag1,2, Aaron P Thrift3,4. 1. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 2. Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA. 3. Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. aaron.thrift@bcm.edu. 4. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. aaron.thrift@bcm.edu.
Abstract
BACKGROUND: Efforts to reduce mortality from esophageal adenocarcinoma (EA) have focused on screening and surveillance of Barrett's esophagus (BE). AIMS: We sought to determine the frequency of prior diagnosis of BE in patients with EA and to evaluate the impact of a prior BE diagnosis on mortality in EA patients. METHODS: This was a retrospective cohort study of patients diagnosed with EA in the VA during 2002-2016. We compared the distributions of EA stage and receipt of treatment between EA patients with and without a prior BE diagnosis and used Cox proportional hazards models to compare mortality risk (all-cause and cancer specific) unadjusted and adjusted for stage and treatment to assess their impact on any survival differences. RESULTS: Among 8564 EA patients, only 4.9% had a prior BE diagnosis. The proportion with prior BE diagnosis increased from 3.2% in EA patients diagnosed during 2005-2007 to 7.0% in those diagnosed during 2014-2016. EA patients with a prior BE diagnosis were more likely to have stage 1 disease and receive any treatment. A prior BE diagnosis was associated with lower all-cause mortality risk (hazard ratio [HR] unadjusted for stage, 0.69; 95% CI, 0.61-0.80), which was largely explained by the earlier stage of EA at the time of diagnosis (HR adjusted for stage, 0.87; 95% CI, 0.75-0.99). There was no evidence of lead time bias or length time bias. CONCLUSIONS: Prior diagnosis of BE was associated with better survival, largely due to earlier EA stage at diagnosis.
BACKGROUND: Efforts to reduce mortality from esophageal adenocarcinoma (EA) have focused on screening and surveillance of Barrett's esophagus (BE). AIMS: We sought to determine the frequency of prior diagnosis of BE in patients with EA and to evaluate the impact of a prior BE diagnosis on mortality in EA patients. METHODS: This was a retrospective cohort study of patients diagnosed with EA in the VA during 2002-2016. We compared the distributions of EA stage and receipt of treatment between EA patients with and without a prior BE diagnosis and used Cox proportional hazards models to compare mortality risk (all-cause and cancer specific) unadjusted and adjusted for stage and treatment to assess their impact on any survival differences. RESULTS: Among 8564 EA patients, only 4.9% had a prior BE diagnosis. The proportion with prior BE diagnosis increased from 3.2% in EA patients diagnosed during 2005-2007 to 7.0% in those diagnosed during 2014-2016. EA patients with a prior BE diagnosis were more likely to have stage 1 disease and receive any treatment. A prior BE diagnosis was associated with lower all-cause mortality risk (hazard ratio [HR] unadjusted for stage, 0.69; 95% CI, 0.61-0.80), which was largely explained by the earlier stage of EA at the time of diagnosis (HR adjusted for stage, 0.87; 95% CI, 0.75-0.99). There was no evidence of lead time bias or length time bias. CONCLUSIONS: Prior diagnosis of BE was associated with better survival, largely due to earlier EA stage at diagnosis.
Authors: Leah L Zullig; George L Jackson; Raye Anne Dorn; Dawn T Provenzale; Rebecca McNeil; Catherine M Thomas; Michael J Kelley Journal: Mil Med Date: 2012-06 Impact factor: 1.437
Authors: Hashem B El-Serag; Aanand D Naik; Zhigang Duan; Mohammad Shakhatreh; Ashley Helm; Amita Pathak; Marilyn Hinojosa-Lindsey; Jason Hou; Theresa Nguyen; John Chen; Jennifer R Kramer Journal: Gut Date: 2015-08-26 Impact factor: 23.059
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: George L Jackson; L Douglas Melton; David H Abbott; Leah L Zullig; Diana L Ordin; Steven C Grambow; Natia S Hamilton; S Yousuf Zafar; Ziad F Gellad; Michael J Kelley; Dawn Provenzale Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Stephen W Duffy; Iris D Nagtegaal; Matthew Wallis; Fay H Cafferty; Nehmat Houssami; Jane Warwick; Prue C Allgood; Olive Kearins; Nancy Tappenden; Emma O'Sullivan; Gill Lawrence Journal: Am J Epidemiol Date: 2008-05-25 Impact factor: 4.897
Authors: Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker Journal: Gut Date: 2013-10-28 Impact factor: 23.059
Authors: Melissa Schmidt; Richard J Hackett; Ann-Marie Baker; Stuart A C McDonald; Michael Quante; Trevor A Graham Journal: Nat Rev Gastroenterol Hepatol Date: 2021-11-02 Impact factor: 46.802
Authors: Joel H Rubenstein; Richard R Evans; Jennifer A Burns; Maria E Arasim; Ji Zhu; Akbar K Waljee Journal: Gastroenterology Date: 2021-12-20 Impact factor: 22.682
Authors: Judith Offman; Francesca Pesola; Rebecca C Fitzgerald; Willie Hamilton; Peter Sasieni Journal: Cancer Med Date: 2021-12-16 Impact factor: 4.452